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Abstract
Objective To determine the age distribution of 
patients and the total drug cost.  To establish the average 
cost per age group and identify factors that may influence 
cost.
Method A pilot study was conducted by selecting 
by convenience sampling a number of patients over 18 
years who were registered in the Pharmacy of Your Choice 
scheme with a community pharmacy where the study was 
carried out.   For each patient, type, frequency and cost 
of medication supplied were identified from treatment 
cards and from Government Health Procurement Services 
(GHPS).
Key findings Data was collected for 491 patients 
(aged between18-98 years) were 272 (55%) were females 
and 10% (n = 47) were institutionalised.  Eight percent 
(n=395) were prescribed drugs for cardiovascular diseases 
which constituted 50% of the total drug expenditure. Daily 
cost per patient was one euro.  Pearson correlation value 
(p<0.05) revealed a significant relationship between the 
increase in cost, unit doses and number of diseases with 
increasing age, between gender and different settings.  
Gender variation between drug categories was not 
significant (p>0.05).
Conclusions Cost of drug treatment is vital 
information that financing providers and policy makers 
require for the allocation of budgets.  Findings suggest 
that populations are ageing, cost increases with age and 
that gender and setting influence the treatment being 
provided.
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A PILOT STUDY TO DETERMINE THE COST OF 
PHARMACEUTICAL DRUG TREATMENT FOR CHRONIC 
CONDITIONS PRESCRIBED IN RELATION TO PATIENTS’ AGE
Introduction 
The cost of treatment is a prominent topic discussed all 
over the world.  In view of population ageing1, strategies 
that sustain health, such as social security funds, total 
or partial reimbursement and co-payments, adopted 
in various countries are increasing the pressures on the 
financing providers which include governments and 
insurances.
Availability and price of drug together with the age 
and socio-economic status of the patient influence the 
drug treatment prescribed and its benefit.  The larger 
proportion of the population are elderly, who in general 
are dependent on social security funds, requiring long-
term treatment for a number of chronic conditions.2    
Locally, the state provides drug treatment for chronic 
conditions free of charge.3   The ever increasing number 
of eligible patients requiring treatment impacts the 
healthcare costs and makes review of drug treatment and 
cost vital. The aim of the study was to determine the cost 
of chronic drug treatment in relation to increasing age.
Method
sTUDy DEsIgN
This was a pilot study performed on a sample of patients 
(491) aged 18 years and over, selected by convenience 
sampling, that collect their free medication supplied by 
the government from a  pharmacy in Malta which is part 
of the POYC scheme.  The study was approved by the 
Research Ethics Committee of the University of Malta.  
The age and gender of all the patients who took part in the 
study were recorded on a data collection sheet.  Patients 
were assigned a code, ensuring confidentiality.  Patient 
treatment cards were reviewed and the four week drug 
treatments were documented.  The patient setting was 
also noted.  The British National Formulary4 was used as a 
guide to the main drug classes.  The prices of all tenders 
procured by the government for each drug identified was 
supplied by the Director of GHPS of Malta5.  All prices were 
quoted in the Euro currency.  The average unit price of 
each item was calculated.
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DATA HANDlINg AND sTATIsTICAl ANAlysIs
A data collection sheet was used to extract required data.  
The patients were ranked in ascending order according 
to age and were segmented in 5 year intervals.  The data 
was imported into a MySQL database which facilitated 
the extraction of any required information.  The age 
distribution of the sample population was estimated and 
was categorised by gender.
Statistical analysis was carried out using SPSS PASW 
version 17.  Descriptive statistics on the population 
characteristics were performed.  ANOVA tests were used 
to compare the means of cost, unit doses and number 
of different drug categories between age groups.  Chi-
squared tests of association were used to compare the 
prevalence between men and women and between 
settings.
Results 
PATIENT CHARACTERIsTICs
A total of 491 patients aged between 18 and 98 years were 
recruited in the study.  The mean age was 65.9 years (SD = 
±14.9), the mode 65 years and median age 66 years.  The 
60-64 years age group had the highest number of patients 
(n=75) followed by that of 65-69 years (n=71)  (Figure 1).   
The gender distribution was 45% (n=219) males and 55% 
(272) females. The setting for the patients was 10% (n=47) 
were institutionalised and had a mean age of 83 years  
(range 58–98 years) while those living in the community 
had a mean age of 64  (range 18 -98 years).
DRUg CATEgORIEs
Fifteen drug categories were identified.  Drugs used 
for the cardiovascular system (CVS) constituted the 
largest proportion of prescriptions.  Eighty percent of 
patients (n=395) consumed at least one type of CVS 
drug which accounted for the observed 50% of the total 
drug expenditure for the whole sample.  Drugs used 
for the central nervous system (CNS) and the endocrine 
system (END sys.) constituted 18% and 11% of the total 
expenditure respectively.  The daily cost per patient was 
74c for CNS drugs and 64c for CVS drugs (Figure 2). 
TREATMENT COsT
The daily total cost for the drugs provided to the whole 
sample population amounted to €491.43c, which is 
approximately equivalent to €1 per patient.  
Figures 3 and 4 show how the average and total cost of 
drug treatment vary with increasing age by both genders 
and settings of the patient.  The average daily cost and 
unit doses consumed and the number of diseases suffered 
by patients over 65 years was higher than for those under 
65 years. (€1.18, 11 doses and 10 diseases as opposed 
to €0.88c, 9 and 5 respectively).  Pearson correlation 
coefficient (0) revealed a significant difference between 
age, gender and setting (P<0.05).   Differences (P<0.05) 
between the different drug categories prescribed in terms 
of cost, unit doses and number of patients suffering from a 
particular disease for patients living in nursing homes were 
observed to be significantly higher (p<0.05). Differences 
observed between gender were not significant (p>0.05).
Discussion 
The cost of pharmaceutical drug treatment reflects a 
fraction of the total treatment cost. This study showed 
that the direct cost posed by the pharmaceutical drug 
treatment is dependent on the price of the procured drug 
product, the units consumed by each patient, the duration 
of treatment, the number of different drugs prescribed, 
and the total number of patients taking the drug/s.  Other 
factors such as the age and gender of the patient were 
found to influence the overall cost. 
Findings were consistent to data obtained in other studies.  
In a Dutch study conducted in 2002, the health care costs 
were observed to increase with increasing age and showed 
higher values for women both for acute and long term 
care.6  Furthermore, a retrospective case-control study 
carried out in the UK, revealed that the cost of therapeutic 
drugs for patients living in nursing homes was more than 
double when compared with those of the community.7 
The age distribution of the patients in this study is 
consistent with population age distribution observed 
nationally and worldwide.  
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The observed high cost in the older age groups could 
be explained by the prescription of more expensive 
treatment. Studies revealed that social class appears to 
relate to polypharmacy and use of more CNS drugs.8  
Higher costs imposed by the female gender could be 
explained by the fact that they are more in number 
and have longer life expectancy; they tend to consume 
higher quantities of drugs and tend to suffer from more 
conditions such as osteoarthritis.  The number of different 
diseases increases with age. 
Review of drug treatment prescribed shows disease 
prevalence to be similar to that in European countries.9  
As reported in previous studies the occurrence of certain 
diseases such as CVS and CNS, is age dependent whereas, 
conditions such as asthma tend to be more controlled 
with increasing age.10 The Eurofamcare report for Malta 
provides information on the number of institutionalised 
persons till 2004.11  A large proportion of the elderly 
are now making use of these facilities due to increased 
morbidities and demands on care.  The higher costs 
imposed by instituitionalised patients could be explained 
by the fact that, in most instances, medication is provided 
under supervision while patients living in the community 
may skip or refuse to take their medication.  
The replacement of old drugs with new, more effective, 
better quality drugs could have contributed to the 
increased costs observed.  Pharmaco-economic studies are 
important tools that help to select the most economically 
feasible and medically appropriate drug treatments.  The 
search by governments and health insurers for cheaper 
therapeutic alternatives underlines the importance of 
generic medicines.12 
Results obtained can be extrapolated for the whole 
population and can help determine the total yearly cost for 
all the patients and hence allocate the required resources.  
Knowledge on the number of patients who are eligible 
for drug treatment and their characteristics is vital and 
can serve multiple purposes.  Documentation of drug 
treatment helps to spot trends in prescribing, unnecessary 
drug use and polypharmacy.13,14  Drug review might 
suggest that certain medication is prescribed to overcome 
adverse effects imposed by other drug treatment 
taken concurrently.  Elderly patients are more likely to 
experience side effects than their younger counterparts 
due to age-related changes in pharmacodynamic and 
pharmacokinetics.  Inappropriate prescribing can be the 
result of restrictive government drug formularies and lack 
of consultation with pharmacists.
Conclusion
In view of population ageing, long-term benefits towards 
improved quality of life and cost savings in terms of 
decreased acute episodes and hospitalisation should be 
the objectives of policy makers when designing protocols 
and procuring drugs to be included in formularies.  
Availability of cheaper, good quality generics help 
minimise the overall cost.  The identification of factors 
influencing the total cost and establishment of the average 
drug treatment cost per patient are essential tools that 
enable policy makers to allocate the required resources.
“Cost of drug 
treatment is vital 
information 
that financing 
providers and 
policy makers 
require for the 
allocation of 
budgets”
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“long-term benefits towards 
improved quality of life and cost 
savings in terms of decreased acute 
episodes and hospitalisation should 
be the objectives of policy makers”
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Figure 1: Age distribution of the total population under study categorised by gender
Figure 2: Different drug classes prescribed in the total sample (including four weekly cost and includes 
the number of patients taking the specified drug classes).  
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Figure 3: Average 4 weekly cost in euros for male and females according to age 
 
Figure 4: The average 4 weekly drug expenditure on patients living in the community 
and those living in nursing homes.
